AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. SOLV
  4. [8-K] Solventum Corporation Reports Material Event

[8-K] Solventum Corporation Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Solventum has amended its transaction agreement with Thermo Fisher Scientific regarding the sale of its purification and filtration business. Key changes include:

  • Excluding the drinking water filtration business from the sale
  • Reducing purchase price from $4.10 billion to $4.00 billion
  • Adding potential $75 million payment to Solventum upon future sale of water business or after 3 years
  • Transaction still expected to close by end of 2025

Financial impact: The retention of water business will increase previously estimated annual EPS accretion beyond 15-20 cents, but reduce projected improvements in gross margin (was 200bps) and operating margin (was 100bps). Updated estimates will be provided during Q2 earnings call. Net proceeds will primarily be used for debt reduction. The amendment aims to decrease complexity and potentially accelerate closing timeline.

Solventum ha modificato il suo accordo di transazione con Thermo Fisher Scientific riguardo alla vendita del suo business di purificazione e filtrazione. Le principali modifiche includono:

  • Esclusione del business della filtrazione dell'acqua potabile dalla vendita
  • Riduzione del prezzo di acquisto da 4,10 miliardi di dollari a 4,00 miliardi di dollari
  • Aggiunta di un potenziale pagamento di 75 milioni di dollari a Solventum in caso di futura vendita del business dell'acqua o dopo 3 anni
  • La transazione 猫 ancora prevista per concludersi entro la fine del 2025

Impatto finanziario: La retention del business dell'acqua aumenter脿 l'incremento stimato annuale dell'utile per azione oltre i 15-20 centesimi, ma ridurr脿 i miglioramenti previsti nel margine lordo (prima 200 punti base) e nel margine operativo (prima 100 punti base). Le stime aggiornate saranno fornite durante la conference call dei risultati del secondo trimestre. I proventi netti saranno principalmente utilizzati per la riduzione del debito. L'emendamento mira a ridurre la complessit脿 e potenzialmente accelerare i tempi di chiusura.

Solventum ha modificado su acuerdo de transacci贸n con Thermo Fisher Scientific respecto a la venta de su negocio de purificaci贸n y filtraci贸n. Los cambios clave incluyen:

  • Exclusi贸n del negocio de filtraci贸n de agua potable de la venta
  • Reducci贸n del precio de compra de
  • Adici贸n de un posible pago de $75 millones a Solventum tras una futura venta del negocio del agua o despu茅s de 3 a帽os
  • Se espera que la transacci贸n se cierre antes de finales de 2025

Impacto financiero: La retenci贸n del negocio del agua aumentar谩 la estimaci贸n previa de incremento anual de BPA en m谩s de 15-20 centavos, pero reducir谩 las mejoras proyectadas en el margen bruto (antes 200 puntos b谩sicos) y el margen operativo (antes 100 puntos b谩sicos). Se proporcionar谩n estimaciones actualizadas durante la llamada de resultados del segundo trimestre. Los ingresos netos se usar谩n principalmente para la reducci贸n de deuda. La enmienda busca disminuir la complejidad y potencialmente acelerar el cronograma de cierre.

Solventum鞚赌 Thermo Fisher Scientific瓿检潣 瓯半灅 瓿勳暯鞚� 靾橃爼頃橃棳 鞝曧檾 氚� 鞐臣 靷梾 毵り皝鞐� 甏�頃� 氤�瓴� 靷暛鞚� 氚滍憸頄堨姷雼堧嫟. 欤检殧 氤�瓴� 靷暛鞚赌 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 鞚岇毄靾� 鞐臣 靷梾鞚� 毵り皝 雽�靸侅棎靹� 鞝滌櫢
  • 毵るГ 臧�瓴╈潉 41鞏� 雼煬鞐愳劀 40鞏� 雼煬搿� 鞚疙晿
  • 頄ロ泟 氍� 靷梾 毵り皝 鞁� 霕愲姅 3雲� 頉勳棎 Solventum鞐� 7500毵� 雼煬 歆�旮� 臧�電レ劚 於旉皜
  • 瓯半灅電� 鞐爠頌� 2025雲� 毵愱箤歆� 鞕勲霅� 鞓堨爼

鞛 鞓來枼: 氍� 靷梾 鞙犾搿� 鞐瓣皠 欤茧嫻靾滌澊鞚� 歃濌皜鞙澊 旮办〈 鞓堨儊旃橃澑 15~20靹柬姼 鞚挫儊鞙茧 靸侅姽頃橃毵�, 齑濎澊鞚惦(旮办〈 200bp)瓿� 鞓侅梾鞚挫澋毳�(旮办〈 100bp)鞚� 臧滌劆韽澏� 臧愳唽頃� 鞝勲鞛呺媹雼�. 鞐呺嵃鞚错姼霅� 於旍爼旃橂姅 2攵勱赴 鞁れ爜 氚滍憸 欷� 鞝滉车霅� 鞓堨爼鞛呺媹雼�. 靾滌垬鞚奠澏� 欤茧 攵�毂� 靸來櫂鞐� 靷毄霅╇媹雼�. 鞚措矆 靾橃爼鞚赌 氤奠灐靹膘潉 欷勳澊瓿� 瓯半灅 鞕勲 鞁滉赴毳� 鞎炿嫻旮瓣赴 鞙勴暅 氇╈爜鞛呺媹雼�.

Solventum a modifi茅 son accord de transaction avec Thermo Fisher Scientific concernant la vente de son activit茅 purification et filtration. Les principaux changements incluent :

  • Exclusion de l'activit茅 filtration d'eau potable de la vente
  • R茅duction du prix d'achat de 4,10 milliards de dollars 脿 4,00 milliards de dollars
  • Ajout d'un paiement potentiel de 75 millions de dollars 脿 Solventum lors d'une future vente de l'activit茅 eau ou apr猫s 3 ans
  • La transaction devrait toujours 锚tre finalis茅e d'ici la fin 2025

Impact financier : La conservation de l'activit茅 eau augmentera l'accroissement annuel estim茅 du BPA de plus de 15-20 cents, mais r茅duira les am茅liorations projet茅es de la marge brute (pr茅c茅demment 200 points de base) et de la marge op茅rationnelle (pr茅c茅demment 100 points de base). Des estimations mises 脿 jour seront fournies lors de la conf茅rence t茅l茅phonique des r茅sultats du deuxi猫me trimestre. Les recettes nettes seront principalement utilis茅es pour r茅duire la dette. L'amendement vise 脿 diminuer la complexit茅 et potentiellement acc茅l茅rer le calendrier de cl么ture.

Solventum hat seine Transaktionsvereinbarung mit Thermo Fisher Scientific bez眉glich des Verkaufs seines Gesch盲fts f眉r Reinigung und Filtration ge盲ndert. Wichtige 脛nderungen umfassen:

  • Ausnahme des Trinkwasserfiltrationsgesch盲fts vom Verkauf
  • Reduzierung des Kaufpreises von 4,10 Milliarden USD auf 4,00 Milliarden USD
  • Hinzuf眉gung einer m枚glichen 75 Millionen USD Zahlung an Solventum bei einem zuk眉nftigen Verkauf des Wassergesch盲fts oder nach 3 Jahren
  • Die Transaktion soll weiterhin bis Ende 2025 abgeschlossen sein

Finanzielle Auswirkungen: Der Verbleib des Wassergesch盲fts wird die zuvor gesch盲tzte j盲hrliche Ergebnissteigerung pro Aktie um mehr als 15-20 Cent erh枚hen, jedoch die erwarteten Verbesserungen der Bruttomarge (vorher 200 Basispunkte) und der operativen Marge (vorher 100 Basispunkte) verringern. Aktualisierte Sch盲tzungen werden w盲hrend der Ergebnispr盲sentation im zweiten Quartal bereitgestellt. Die Nettoerl枚se werden haupts盲chlich zur Schuldentilgung verwendet. Die 脛nderung zielt darauf ab, die Komplexit盲t zu reduzieren und den Abschlusszeitraum m枚glicherweise zu beschleunigen.

Positive
  • None.
Negative
  • None.

Solventum ha modificato il suo accordo di transazione con Thermo Fisher Scientific riguardo alla vendita del suo business di purificazione e filtrazione. Le principali modifiche includono:

  • Esclusione del business della filtrazione dell'acqua potabile dalla vendita
  • Riduzione del prezzo di acquisto da 4,10 miliardi di dollari a 4,00 miliardi di dollari
  • Aggiunta di un potenziale pagamento di 75 milioni di dollari a Solventum in caso di futura vendita del business dell'acqua o dopo 3 anni
  • La transazione 猫 ancora prevista per concludersi entro la fine del 2025

Impatto finanziario: La retention del business dell'acqua aumenter脿 l'incremento stimato annuale dell'utile per azione oltre i 15-20 centesimi, ma ridurr脿 i miglioramenti previsti nel margine lordo (prima 200 punti base) e nel margine operativo (prima 100 punti base). Le stime aggiornate saranno fornite durante la conference call dei risultati del secondo trimestre. I proventi netti saranno principalmente utilizzati per la riduzione del debito. L'emendamento mira a ridurre la complessit脿 e potenzialmente accelerare i tempi di chiusura.

Solventum ha modificado su acuerdo de transacci贸n con Thermo Fisher Scientific respecto a la venta de su negocio de purificaci贸n y filtraci贸n. Los cambios clave incluyen:

  • Exclusi贸n del negocio de filtraci贸n de agua potable de la venta
  • Reducci贸n del precio de compra de
  • Adici贸n de un posible pago de $75 millones a Solventum tras una futura venta del negocio del agua o despu茅s de 3 a帽os
  • Se espera que la transacci贸n se cierre antes de finales de 2025

Impacto financiero: La retenci贸n del negocio del agua aumentar谩 la estimaci贸n previa de incremento anual de BPA en m谩s de 15-20 centavos, pero reducir谩 las mejoras proyectadas en el margen bruto (antes 200 puntos b谩sicos) y el margen operativo (antes 100 puntos b谩sicos). Se proporcionar谩n estimaciones actualizadas durante la llamada de resultados del segundo trimestre. Los ingresos netos se usar谩n principalmente para la reducci贸n de deuda. La enmienda busca disminuir la complejidad y potencialmente acelerar el cronograma de cierre.

Solventum鞚赌 Thermo Fisher Scientific瓿检潣 瓯半灅 瓿勳暯鞚� 靾橃爼頃橃棳 鞝曧檾 氚� 鞐臣 靷梾 毵り皝鞐� 甏�頃� 氤�瓴� 靷暛鞚� 氚滍憸頄堨姷雼堧嫟. 欤检殧 氤�瓴� 靷暛鞚赌 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 鞚岇毄靾� 鞐臣 靷梾鞚� 毵り皝 雽�靸侅棎靹� 鞝滌櫢
  • 毵るГ 臧�瓴╈潉 41鞏� 雼煬鞐愳劀 40鞏� 雼煬搿� 鞚疙晿
  • 頄ロ泟 氍� 靷梾 毵り皝 鞁� 霕愲姅 3雲� 頉勳棎 Solventum鞐� 7500毵� 雼煬 歆�旮� 臧�電レ劚 於旉皜
  • 瓯半灅電� 鞐爠頌� 2025雲� 毵愱箤歆� 鞕勲霅� 鞓堨爼

鞛 鞓來枼: 氍� 靷梾 鞙犾搿� 鞐瓣皠 欤茧嫻靾滌澊鞚� 歃濌皜鞙澊 旮办〈 鞓堨儊旃橃澑 15~20靹柬姼 鞚挫儊鞙茧 靸侅姽頃橃毵�, 齑濎澊鞚惦(旮办〈 200bp)瓿� 鞓侅梾鞚挫澋毳�(旮办〈 100bp)鞚� 臧滌劆韽澏� 臧愳唽頃� 鞝勲鞛呺媹雼�. 鞐呺嵃鞚错姼霅� 於旍爼旃橂姅 2攵勱赴 鞁れ爜 氚滍憸 欷� 鞝滉车霅� 鞓堨爼鞛呺媹雼�. 靾滌垬鞚奠澏� 欤茧 攵�毂� 靸來櫂鞐� 靷毄霅╇媹雼�. 鞚措矆 靾橃爼鞚赌 氤奠灐靹膘潉 欷勳澊瓿� 瓯半灅 鞕勲 鞁滉赴毳� 鞎炿嫻旮瓣赴 鞙勴暅 氇╈爜鞛呺媹雼�.

Solventum a modifi茅 son accord de transaction avec Thermo Fisher Scientific concernant la vente de son activit茅 purification et filtration. Les principaux changements incluent :

  • Exclusion de l'activit茅 filtration d'eau potable de la vente
  • R茅duction du prix d'achat de 4,10 milliards de dollars 脿 4,00 milliards de dollars
  • Ajout d'un paiement potentiel de 75 millions de dollars 脿 Solventum lors d'une future vente de l'activit茅 eau ou apr猫s 3 ans
  • La transaction devrait toujours 锚tre finalis茅e d'ici la fin 2025

Impact financier : La conservation de l'activit茅 eau augmentera l'accroissement annuel estim茅 du BPA de plus de 15-20 cents, mais r茅duira les am茅liorations projet茅es de la marge brute (pr茅c茅demment 200 points de base) et de la marge op茅rationnelle (pr茅c茅demment 100 points de base). Des estimations mises 脿 jour seront fournies lors de la conf茅rence t茅l茅phonique des r茅sultats du deuxi猫me trimestre. Les recettes nettes seront principalement utilis茅es pour r茅duire la dette. L'amendement vise 脿 diminuer la complexit茅 et potentiellement acc茅l茅rer le calendrier de cl么ture.

Solventum hat seine Transaktionsvereinbarung mit Thermo Fisher Scientific bez眉glich des Verkaufs seines Gesch盲fts f眉r Reinigung und Filtration ge盲ndert. Wichtige 脛nderungen umfassen:

  • Ausnahme des Trinkwasserfiltrationsgesch盲fts vom Verkauf
  • Reduzierung des Kaufpreises von 4,10 Milliarden USD auf 4,00 Milliarden USD
  • Hinzuf眉gung einer m枚glichen 75 Millionen USD Zahlung an Solventum bei einem zuk眉nftigen Verkauf des Wassergesch盲fts oder nach 3 Jahren
  • Die Transaktion soll weiterhin bis Ende 2025 abgeschlossen sein

Finanzielle Auswirkungen: Der Verbleib des Wassergesch盲fts wird die zuvor gesch盲tzte j盲hrliche Ergebnissteigerung pro Aktie um mehr als 15-20 Cent erh枚hen, jedoch die erwarteten Verbesserungen der Bruttomarge (vorher 200 Basispunkte) und der operativen Marge (vorher 100 Basispunkte) verringern. Aktualisierte Sch盲tzungen werden w盲hrend der Ergebnispr盲sentation im zweiten Quartal bereitgestellt. Die Nettoerl枚se werden haupts盲chlich zur Schuldentilgung verwendet. Die 脛nderung zielt darauf ab, die Komplexit盲t zu reduzieren und den Abschlusszeitraum m枚glicherweise zu beschleunigen.

FALSE000196473800019647382025-06-252025-06-25


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 25, 2025    
Solventum Corporation
(Exact name of registrant as specified in its charter)
Delaware001-4196892-2008841
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)

3M Center, Building 275-6W
2510 Conway Avenue East
Maplewood, MN 55144
(Address of Principal Executive Offices, including Zip code)

(651) 733-1110
(Registrant’s telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareSOLVNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 1.01
Entry into a Material Definitive Agreement.

As previously disclosed, on February 25, 2025, Solventum Corporation, a Delaware corporation (“Solventum”) and Thermo Fisher Scientific Inc., a Delaware corporation (“Buyer”), entered into a Transaction Agreement (the “Initial Agreement”), pursuant to which, subject to the satisfaction or waiver of certain conditions, Buyer agreed to acquire from Solventum certain assets and liabilities related to Solventum’s purification and filtration business.

On June 25, 2025, Solventum and Buyer entered into an Amended and Restated Transaction Agreement (the “Agreement”) to exclude Solventum’s drinking water filtration business (the “Water Business”) from the scope of the purification and filtration business to be acquired by Buyer and reduce the cash consideration payable for the acquired business at the closing of the transaction from approximately $4.10 billion to approximately $4.00 billion, with net proceeds still intended to be used primarily to pay down debt. The closing purchase price continues to be subject to customary adjustments for closing cash and debt, unpaid transaction expenses and working capital as set forth in the Agreement.

The Agreement is expected to decrease complexity and potentially accelerate time to close the transaction, which we previously disclosed is anticipated by the end of 2025. In addition, the Agreement creates future value opportunities from the Water Business. Buyer will be entitled to receive a payment of up to $75 million from Solventum either upon a sale of the Water Business or after an agreed upon 3-year period.

Keeping the Water Business will increase our previously estimated annual EPS accretion of 15 to 20 cents. However, it will also reduce the previously projected improvements to gross margin and operating margin, which were 200 and 100 basis points, respectively. We will share updated estimates during our second quarter earnings call.

The Agreement is generally consistent with the terms of the Initial Agreement, except for modifications to reflect the removal of the Water Business including non-compete and related provisions and certain reverse services, manufacturing and supply agreements to support the Water Business.

The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the text of the Agreement, a copy of which is attached hereto as Exhibit 2.1, and the terms of which are incorporated herein by reference. The foregoing description of the Agreement is not intended to provide any other factual information about the acquired business, the Water Business, Solventum, Buyer or their respective businesses.

Forward Looking Statements

This Current Report on Form 8-K contains statements that relate to future events and expectations and, as such, constitute forward-looking statements that involve risk and uncertainties. Forward-looking statements include those containing such words as “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “guidance,” “intends,” “may,” “outlook,” “plans,” “projects,” “seeks,” “sees,” “should,” “targets,” “will,” “would,” and other words and terms of similar meaning. All statements that reflect Solventum’s expectations, assumptions, or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the sale of the business, the satisfaction of closing conditions and the likelihood of consummation of the transaction, the expected time period to consummate the transaction, the anticipated benefits of the transaction, and the anticipated use of proceeds from the transaction. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and changes in circumstances that are difficult to predict. Although Solventum believes that the expectations reflected in any forward-looking statements it makes are based on reasonable assumptions, it can give no assurance that these expectations, including the expected impact of the divestiture of the business, will be attained and it is possible that actual results may differ materially from those indicated by these forward-looking statements due to a variety of


risks and uncertainties, include, among others, risks related to the ability to realize the anticipated benefits of the divestiture, including the possibility that expected benefits of portfolio optimization will not be realized or will not be realized within the expected time frame; delays in the closing of the transaction due to regulatory approvals or other closing conditions; unfavorable reaction to the divestiture by customers, competitors, suppliers, and employees, making it more difficult to maintain business and operational relationships; disruption from the transaction; significant transaction costs; and other unknown liabilities.

Changes in such assumptions or factors could produce significantly different results. A further description of these factors is located under “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” in Solventum’s periodic reports on file with the U.S. Securities & Exchange Commission. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments.

Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Number
Exhibit Description
2.1
Amended and Restated Transaction Agreement by and between Solventum Corporation as Seller and Thermo Fisher Scientific Inc. as Buyer dated as of June 25, 2025.
104.1Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 25, 2025SOLVENTUM CORPORATION
By:/s/ Wayde McMillan
Wayde McMillan
Executive Vice President and Chief Financial Officer



Source:

FAQ

What is the new purchase price for SOLV's purification and filtration business sale to Thermo Fisher?

The cash consideration for SOLV's purification and filtration business has been reduced from $4.10 billion to $4.00 billion, after excluding the drinking water filtration business from the transaction. The closing purchase price remains subject to customary adjustments for closing cash and debt, unpaid transaction expenses and working capital.

Why did SOLV amend its transaction agreement with Thermo Fisher on June 25, 2025?

SOLV amended the agreement to exclude its drinking water filtration business from the sale, which is expected to decrease complexity and potentially accelerate the time to close the transaction. The amendment also creates future value opportunities from the Water Business, with Thermo Fisher entitled to receive up to $75 million from SOLV either upon a sale of the Water Business or after an agreed 3-year period.

How will SOLV's retention of the Water Business impact its financial metrics?

Keeping the Water Business will increase SOLV's previously estimated annual EPS accretion of 15-20 cents. However, it will reduce the previously projected improvements to gross margin and operating margin, which were 200 and 100 basis points respectively. Updated estimates will be shared during the second quarter earnings call.

When is SOLV expected to close the Thermo Fisher transaction?

The transaction is anticipated to close by the end of 2025, with the amended agreement potentially accelerating the time to close. The closing remains subject to customary conditions including regulatory approvals.

How does SOLV plan to use the proceeds from the Thermo Fisher transaction?

The net proceeds from the $4.00 billion transaction are intended to be used primarily to pay down SOLV's debt, as stated in the filing.
Stock SOLV logo
Solventum Corporation

NYSE:SOLV

SOLV Rankings

#770 Ranked by Market Cap
N/A Ranked by Dividends

SOLV Latest News

Aug 13, 2025
Solventum Announces Pricing of Secondary Offering of Common Stock
Aug 13, 2025
Solventum Announces Launch of Secondary Offering of Common Stock
Aug 7, 2025
Solventum Reports Second Quarter 2025 Financial Results
Jul 17, 2025
Solventum to Report Second Quarter Fiscal 2025 Earnings on August 7, 2025
Jun 18, 2025
Solventum Named a Best Company to Work for by U.S. News & World Report

SOLV Latest SEC Filings

Aug 13, 2025
[S-3ASR] Solventum Corporation SEC Filing
Aug 13, 2025
[8-K] Solventum Corporation Reports Material Event
Aug 13, 2025
[SCHEDULE 13G] Solventum Corporation SEC Filing

SOLV Stock Data

12.46B
138.79M
20%
67.89%
2.23%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
United States
ST. PAUL